5395242026-07-245395242026-07-242026-07-245395242026-07-24in-capmkt:FinancialYear1Member5395242026-07-24in-capmkt:FinancialYear2Member5395242026-07-24in-capmkt:FinancialYear3Member5395242026-07-242026-07-24in-capmkt:FinancialYear1Member5395242026-07-242026-07-24in-capmkt:FinancialYear2Member5395242026-07-242026-07-24in-capmkt:FinancialYear3Memberiso4217:INRxbrli:pure539524Dr. Lal Path Labs Ltd.LALPATHLABNOTLISTEDINE600L01024NewAcquisition (including agreement to acquire)true2026-07-2413:30:002026-07-24The Board of Directors of the Company took note that the Board of Dr Lal PathLabs FZCO, Dubai, Wholly Owned Subsidiary of the Company, approved acquisition of stake in Sunshine Healthcare Limited (“SHL”), Ghana. Dr Lal PathLabs FZCO, DubaiSubsidiarySunshine Healthcare Limited24400000016000000110000000falsefalsetrueHealthcare - DiagnosticsTo strengthen the Company’s presence in Ghana, West AfricaNAtrueThe closing with respect to the investment of the first tranche is expected to be completed by August 31, 2026 or such other date mutually agreed between the parties.Cash380000000The proposed investment will be upto GHS 45.6 Mn. (Equivalent to INR 380 Mn.) for 80% stake to be acquired in first tranche.38000000000.8SHL was incorporated on September 07, 2010, under the laws of Ghana and is engaged in business of providing Healthcare/ Diagnostics services.2025-20262440000002024-20252400000002023-2024217000000GhanaThe aforementioned acquisition does not qualify as a related party transaction. However, due to limitations in the XBRL format, the question, Whether the transaction was conducted at arm's length, provides only a Yes/No dropdown option. We selected Yes; however, this should be interpreted as Not Applicable.